Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nova 301: mRNA-1403 Vaccine for Norovirus Acute Gastroenteritis in Adults
NCT06592794Phase 3Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Sep 2024
- Primary completion
- Feb 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Norovirus Acute Gastroenteritis comparing mRNA-1403 with Placebo (2 arms). Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions, Number of Participants with Unsolicited Adverse Events and 3 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
mRNA-1403
03
Conditions
Norovirus Acute Gastroenteritis
Beyond the preview
Go deeper on NCT06592794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592794.